Our results show that HE4 is not correlated with pathological subtypes and estrogen-sensitivity; thus, unlike estrogen, to some extent, HE4 does not affect those at high risk of endometrial cancer, patients with obesity or diabetes and breast cancer patients on long-term administration of estrogen; that is [17], HE4 expression rate does not affect the pathological types of endometrial cancer and estrogen dependency. This evidence concerns the gene WFDC2 and breast carcinoma.